Alpha 2.0
Login Register
» Authors » Ann Greer

Ann Greer

Explore the profile of Ann Greer including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 16
Citations 473
Followers 0
Related Specialties
Biochemistry
Chemistry
Oncology
Top 10 Co-Authors
Aixin Li
Marco Gottardis
Upender Velaparthi
Dolatrai Vyas
Joan M Carboni
Kurt Zimmermann
Zheng Yang
Warren Hurlburt
Ricardo Attar
Joan Carboni
Published In
Bioorg Med Chem Lett
J Med Chem
Cancer Res
Mol Cancer Ther
Pediatrics
Affiliations
Soon will be listed here.
Recent Articles
1.
IRS2 copy number gain, KRAS and BRAF mutation status as predictive biomarkers for response to the IGF-1R/IR inhibitor BMS-754807 in colorectal cancer cell lines
Huang F, Chang H, Greer A, Hillerman S, Reeves K, Hurlburt W, et al.
Mol Cancer Ther . 2014 Dec; 14(2):620-30. PMID: 25527633
Insulin-like growth factor receptor 1 (IGF-1R)-targeting therapies are currently at an important crossroad given the low clinical response rates seen in unselected patients. Predictive biomarkers for patient selection are critical...
2.
Biochemical and transcriptional profiling to triage additional activities in a series of IGF-1R/IR inhibitors
Ross-Macdonald P, de Silva H, Patel V, Truong A, He A, Neuhaus I, et al.
Bioorg Med Chem . 2011 Dec; 20(6):1961-72. PMID: 22137930
Therapeutic development of a targeted agent involves a series of decisions over additional activities that may be ignored, eliminated or pursued. This paper details the concurrent application of two methods...
3.
Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer
Hou X, Huang F, Macedo L, Harrington S, Reeves K, Greer A, et al.
Cancer Res . 2011 Nov; 71(24):7597-607. PMID: 22042792
Insulin-like growth factor (IGF) signaling has been implicated in the resistance to hormonal therapy in breast cancer. Using a model of postmenopausal, estrogen-dependent breast cancer, we investigated the antitumor effects...
4.
Nonurgent emergency-department care: analysis of parent and primary physician perspectives
Brousseau D, Nimmer M, Yunk N, Nattinger A, Greer A
Pediatrics . 2011 Jan; 127(2):e375-81. PMID: 21242226
Objective: To better understand parental decisions to seek care for their children and physician perceptions of parents' decisions to seek nonurgent emergency-department care. Patients And Methods: In-depth interviews of 26...
5.
Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model
Huang F, Hurlburt W, Greer A, Reeves K, Hillerman S, Chang H, et al.
Cancer Res . 2010 Sep; 70(18):7221-31. PMID: 20807811
Agents targeting insulin-like growth factor-I receptor (IGF-IR), including antibodies and small-molecule inhibitors, are currently in clinical development for the treatment of cancers including sarcoma. However, development of resistance is a...
6.
Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one
Velaparthi U, Saulnier M, Wittman M, Liu P, Frennesson D, Zimmermann K, et al.
Bioorg Med Chem Lett . 2010 Apr; 20(10):3182-5. PMID: 20399649
A series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one were synthesized to modulate CYP3A4 inhibition and improve aqueous solubility of our prototypical compound BMS-536924 (1), while maintaining potent IGF-1R inhibitory activity. Structure-activity and structure-solubility studies...
7.
BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR
Carboni J, Wittman M, Yang Z, Lee F, Greer A, Hurlburt W, et al.
Mol Cancer Ther . 2009 Dec; 8(12):3341-9. PMID: 19996272
BMS-754807 is a potent and reversible inhibitor of the insulin-like growth factor 1 receptor/insulin receptor family kinases (Ki, <2 nmol/L). It is currently in phase I development for the treatment...
8.
Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development
Wittman M, Carboni J, Yang Z, Lee F, Antman M, Attar R, et al.
J Med Chem . 2009 Sep; 52(23):7360-3. PMID: 19778024
This report describes the biological activity, characterization, and SAR leading to 9d (BMS-754807) a small molecule IGF-1R kinase inhibitor in clinical development.
9.
The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors
Huang F, Greer A, Hurlburt W, Han X, Hafezi R, Wittenberg G, et al.
Cancer Res . 2009 Jan; 69(1):161-70. PMID: 19117999
Overexpression and enhanced activity of insulin-like growth factor-I receptor (IGF-IR) in diverse tumor types make it an attractive target for cancer therapy. BMS-536924 is a potent small molecule inhibitor of...
10.
Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor...
Velaparthi U, Wittman M, Liu P, Carboni J, Lee F, Attar R, et al.
J Med Chem . 2008 Sep; 51(19):5897-900. PMID: 18763755
We previously reported that 1 (BMS-536924), a benzimidazole inhibitor of the insulin-like growth factor-1 receptor, had demonstrated in vivo antitumor activity. This lead compound was found to have potent CYP3A4...